Gene Gene synonym Ensembl Gene description Chromosome Position Protein class Evidence Antibody Reliability (IH) Reliability (Mouse Brain) Reliability (IF) Subcellular location Prognostic p-value RNA cancer category RNA tissue category RNA TS RNA TS TPM TPM max in non-specific ABI1 ABI-1, E3B1, SSH3BP1 ENSG00000136754 Abl-interactor 1 10 26746593-26861087 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level CAB008375, HPA029973, HPA068407 Approved Supported Plasma membrane
Cell Junctions Expressed in all Expressed in all cerebral cortex: 87.6 ADGRL2 KIAA0786, LEC1, LPHH1, LPHN2 ENSG00000117114 Adhesion G protein-coupled receptor L2 1 81306160-81992436 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA043447 Approved Plasma membrane
Cell Junctions Endometrial cancer:1.33e-4 (unfavourable), Stomach cancer:3.00e-4 (unfavourable), Liver cancer:9.92e-4 (unfavourable) Expressed in all Mixed thyroid gland: 72.8 AGO2 EIF2C2, hAGO2, Q10 ENSG00000123908 Argonaute RISC catalytic component 2 8 140520156-140635619 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB019309, HPA058075 Approved Supported Nucleoplasm
Cell Junctions Renal cancer:1.82e-5 (unfavourable), Endometrial cancer:1.21e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 11.9 AMOTL1 JEAP ENSG00000166025 Angiomotin like 1 11 94706431-94876753 Predicted intracellular proteins Evidence at protein level HPA001196 Approved Supported Cell Junctions
Cytosol Renal cancer:5.03e-6 (favourable) Expressed in all Expressed in all prostate: 52.2 AMOTL2 LCCP ENSG00000114019 Angiomotin like 2 3 134355874-134375479 Predicted intracellular proteins Evidence at protein level HPA063027 Approved Cell Junctions
Centrosome Endometrial cancer:1.94e-4 (unfavourable) Expressed in all Mixed adipose tissue: 76.4 ANKRA2 ENSG00000164331 Ankyrin repeat, family A (RFXANK-like), 2 5 73552335-73565686 Predicted intracellular proteins Evidence at protein level HPA065263 Approved Plasma membrane
Cell Junctions Expressed in all Expressed in all thyroid gland: 26.1 AQP4 MIWC ENSG00000171885 Aquaporin 4 18 26852038-26865818 Predicted membrane proteins, Transporters Evidence at protein level CAB005079, HPA014784, CAB058689 Supported Supported Supported Plasma membrane
Cell Junctions Tissue enriched Group enriched 17 cerebral cortex: 631.8;lung: 172.2 thyroid gland: 24.3 ARPC1A Arc40, SOP2Hs, SOP2L ENSG00000241685 Actin related protein 2/3 complex, subunit 1A, 41kDa 7 99325898-99388164 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA004334 Approved Approved Cell Junctions
Cytosol Liver cancer:4.70e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 131.0 ASGR1 CLEC4H1 ENSG00000141505 Asialoglycoprotein receptor 1 17 7173431-7179564 Predicted intracellular proteins Evidence at protein level HPA011954, HPA012852 Supported Supported Vesicles
Cell Junctions Tissue enriched Tissue enriched 13 liver: 236.1 testis: 17.7 BRK1 C3orf10, HSPC300, MDS027 ENSG00000254999 BRICK1, SCAR/WAVE actin-nucleating complex subunit 3 10115592-10127190 Predicted intracellular proteins Evidence at protein level HPA060391 Approved Nuclear speckles
Cell Junctions Liver cancer:5.76e-5 (unfavourable) Expressed in all Expressed in all fallopian tube: 223.3 C16orf59 FLJ13909 ENSG00000162062 Chromosome 16 open reading frame 59 16 2460080-2464963 Predicted intracellular proteins Evidence at protein level HPA051394 Uncertain Approved Nucleoplasm
Cell Junctions Liver cancer:2.43e-5 (unfavourable), Lung cancer:7.58e-4 (unfavourable) Expressed in all Tissue enhanced testis: 5.5 lymph node: 2.6 C17orf62 FLJ90469, MGC4368 ENSG00000178927 Chromosome 17 open reading frame 62 17 82442589-82450829 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA045696 Uncertain Approved Plasma membrane
Cell Junctions Renal cancer:6.83e-11 (unfavourable) Expressed in all Expressed in all lymph node: 129.5 CABLES2 C20orf150, dJ908M14.2, ik3-2 ENSG00000149679 Cdk5 and Abl enzyme substrate 2 20 62388632-62407285 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA052138 Approved Nuclear bodies
Cell Junctions Renal cancer:1.24e-6 (unfavourable), Endometrial cancer:5.26e-5 (unfavourable) Expressed in all Tissue enriched 6 testis: 58.3 cerebral cortex: 9.0 CAMK2A CAMKA, CaMKIINalpha, KIAA0968 ENSG00000070808 Calcium/calmodulin-dependent protein kinase II alpha 5 150219491-150290291 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB004330, HPA051783, HPA051785, HPA053973 Supported Supported Plasma membrane
Cell Junctions Tissue enriched Tissue enriched 9 cerebral cortex: 284.4 skeletal muscle: 33.3 CAMK2B CAM2, CAMK2, CAMKB ENSG00000058404 Calcium/calmodulin-dependent protein kinase II beta 7 44217150-44334577 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB006849, HPA026307, HPA051783, HPA051785, HPA053973 Supported Supported Uncertain Plasma membrane
Cell Junctions Mixed Tissue enhanced cerebral cortex: 214.7 skeletal muscle: 46.1 CAMK2D CAMKD ENSG00000145349 Calcium/calmodulin-dependent protein kinase II delta 4 113451032-113761927 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA026281, HPA051783, HPA051785, HPA053973 Approved Supported Plasma membrane
Cell Junctions Expressed in all Expressed in all parathyroid gland: 106.2 CCDC170 bA282P11.1, C6orf97, FLJ23305 ENSG00000120262 Coiled-coil domain containing 170 6 151494030-151621193 Predicted intracellular proteins Evidence at protein level HPA027114, HPA027185 Supported Approved Golgi apparatus
Cell Junctions Endometrial cancer:3.64e-4 (favourable) Mixed Tissue enriched 6 fallopian tube: 52.9 thyroid gland: 9.4 CCDC85C ENSG00000205476 Coiled-coil domain containing 85C 14 99500180-99604026 Predicted intracellular proteins Evidence at protein level HPA058346 Uncertain Approved Nuclear speckles
Cell Junctions Renal cancer:2.60e-5 (favourable), Endometrial cancer:1.44e-4 (unfavourable) Expressed in all Expressed in all esophagus: 31.3 CDH2 CD325, CDHN, NCAD ENSG00000170558 Cadherin 2, type 1, N-cadherin (neuronal) 18 27950966-28177446 CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB000141, CAB018580, HPA058574 Supported Supported Plasma membrane
Cell Junctions Expressed in all Tissue enhanced heart muscle: 125.8;parathyroid gland: 124.0 adrenal gland: 87.7 CDH3 CDHP, PCAD ENSG00000062038 Cadherin 3, type 1, P-cadherin (placental) 16 68636189-68722616 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA001767, CAB002487 Supported Uncertain Cell Junctions
Cytosol Pancreatic cancer:8.43e-4 (unfavourable), Lung cancer:8.53e-4 (unfavourable) Mixed Tissue enhanced skin: 32.0 ovary: 26.9 CDK5RAP2 C48, CEP215, FLJ10867, MCPH3 ENSG00000136861 CDK5 regulatory subunit associated protein 2 9 120388869-120580170 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA035820, HPA046529 Approved Validated Cell Junctions
Centrosome Expressed in all Expressed in all testis: 37.2 CFAP206 C6orf165, dJ382I10.1, FLJ25974 ENSG00000272514 Cilia and flagella associated protein 206 6 87407983-87464465 Predicted intracellular proteins Evidence at protein level HPA044891, HPA072261 Approved Approved Nucleoplasm
Cell Junctions Not detected Group enriched 30 fallopian tube: 35.3;testis: 107.4 lung,thyroid gland: 2.3 CFB BF, BFD, H2-Bf ENSG00000243649 Complement factor B 6 31945650-31952084 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA000951, HPA001817, HPA001832, CAB016381 Supported Uncertain Vesicles
Cell Junctions Renal cancer:1.53e-5 (unfavourable), Breast cancer:2.76e-5 (favourable) Expressed in all Tissue enriched 20 liver: 283.0 stomach: 13.9 CGN KIAA1319 ENSG00000143375 Cingulin 1 151510510-151538692 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB017193, HPA027586, HPA027587, HPA027657 Supported Supported Plasma membrane
Cell Junctions Renal cancer:5.84e-10 (favourable) Expressed in all Tissue enhanced parathyroid gland: 73.3 small intestine: 63.2 CHCHD7 COX23, MGC2217 ENSG00000170791 Coiled-coil-helix-coiled-coil-helix domain containing 7 8 56211686-56218798 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA050783 Approved Approved Cell Junctions
Aggresome Endometrial cancer:1.39e-6 (unfavourable), Renal cancer:9.47e-5 (favourable) Expressed in all Expressed in all ovary: 61.5 CLCA2 CLCRG2 ENSG00000137975 Chloride channel accessory 2 1 86424086-86456558 Predicted membrane proteins Evidence at protein level HPA047192 Supported Supported Nucleus
Cell Junctions Group enriched Tissue enhanced esophagus: 126.9;skin: 102.9 tonsil: 23.5 CLDN2 ENSG00000165376 Claudin 2 X 106900164-106930861 Predicted membrane proteins Evidence at protein level CAB002609, HPA051548 Supported Supported Nucleoplasm
Cell Junctions Thyroid cancer:1.70e-4 (favourable) Group enriched Tissue enhanced gallbladder: 159.7;kidney: 170.5;seminal vesicle: 128.0 epididymis: 40.4 CLDN7 CEPTRL2, CPETRL2, Hs.84359 ENSG00000181885 Claudin 7 17 7259903-7263983 Cancer-related genes, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level CAB013063, HPA014703, HPA073662 Supported Approved Vesicles
Cell Junctions Renal cancer:8.96e-11 (favourable), Thyroid cancer:1.85e-4 (favourable), Stomach cancer:4.09e-4 (favourable) Expressed in all Mixed small intestine: 357.1 CLDN9 ENSG00000213937 Claudin 9 16 3012456-3014505 Predicted membrane proteins Evidence at protein level HPA076613 Supported Vesicles
Cell Junctions Endometrial cancer:2.24e-6 (unfavourable), Stomach cancer:4.67e-4 (unfavourable) Mixed Tissue enhanced parathyroid gland: 3.1 bone marrow: 1.7 CMTR2 AFT, FLJ11171, FTSJD1, MTr2 ENSG00000180917 Cap methyltransferase 2 16 71281389-71289715 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041700, HPA048265 Uncertain Approved Nuclear speckles
Cell Junctions Renal cancer:4.97e-5 (favourable) Expressed in all Mixed testis: 16.2 COBL KIAA0633 ENSG00000106078 Cordon-bleu WH2 repeat protein 7 51016212-51316818 Predicted intracellular proteins Evidence at protein level HPA019033, HPA019167 Supported Approved Plasma membrane
Cell Junctions Renal cancer:5.21e-12 (favourable) Mixed Mixed cerebral cortex: 61.6 COLQ EAD ENSG00000206561 Collagen-like tail subunit (single strand of homotrimer) of asymmetric acetylcholinesterase 3 15450133-15521751 Disease related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA045876 Approved Plasma membrane
Cell Junctions Mixed Tissue enhanced parathyroid gland: 19.2 fallopian tube: 17.4 CTNNA1 CAP102 ENSG00000044115 Catenin (cadherin-associated protein), alpha 1, 102kDa 5 138610967-138935034 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB021089, HPA046119, HPA063535 Approved Validated Plasma membrane
Cell Junctions Renal cancer:7.34e-7 (favourable), Pancreatic cancer:8.02e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 215.4 CXADR CAR ENSG00000154639 Coxsackie virus and adenovirus receptor 21 17512382-17593579 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA003342, CAB005103, HPA030411, HPA030412 Supported Validated Plasma membrane
Cell Junctions Head and neck cancer:3.50e-4 (favourable) Expressed in all Mixed skin: 59.6 DDB2 DDBB, FLJ34321, UV-DDB2, XPE ENSG00000134574 Damage-specific DNA binding protein 2, 48kDa 11 47214465-47239240 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level CAB025912, HPA058406 Supported Supported Nucleoplasm
Cell Junctions Endometrial cancer:1.20e-4 (favourable), Cervical cancer:1.58e-4 (favourable), Breast cancer:7.29e-4 (favourable) Expressed in all Expressed in all skin: 53.8 DDR1 CAK, CD167, EDDR1, NEP, NTRK4, PTK3A, RTK6 ENSG00000204580 Discoidin domain receptor tyrosine kinase 1 6 30876421-30900156 CD markers, Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB010162, CAB025656, HPA057194 Approved Approved Nucleoplasm
Cell Junctions Renal cancer:3.31e-10 (favourable) Expressed in all Mixed cerebral cortex: 51.7 DPEP1 ENSG00000015413 Dipeptidase 1 (renal) 16 89613308-89638456 Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level HPA009426, HPA012783 Supported Approved Nucleus
Cell Junctions Renal cancer:6.84e-4 (favourable) Tissue enriched Tissue enhanced kidney: 262.3;small intestine: 426.5 pancreas: 92.8 DPH1 DPH2L, DPH2L1, OVCA1 ENSG00000108963 Diphthamide biosynthesis 1 17 2030110-2043430 Predicted intracellular proteins Evidence at protein level HPA069750 Approved Nucleoplasm
Cell Junctions Pancreatic cancer:1.78e-5 (favourable) Expressed in all Expressed in all fallopian tube: 30.8 DSC3 CDHF3, DSC, DSC1, DSC2, DSC4 ENSG00000134762 Desmocollin 3 18 30990008-31042815 Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB037328, HPA049265, HPA073937 Supported Validated Plasma membrane
Cell Junctions Urothelial cancer:1.04e-5 (unfavourable) Tissue enhanced Group enriched 11 esophagus: 119.5;skin: 455.7 tonsil: 25.9 EFCAB11 C14orf143 ENSG00000140025 EF-hand calcium binding domain 11 14 89794669-89954777 Predicted intracellular proteins Evidence at transcript level HPA051209 Approved Cell Junctions
Cytosol Expressed in all Tissue enhanced testis: 59.8 fallopian tube: 17.1 ELMO3 CED-12, CED12, ELMO-3, FLJ13824 ENSG00000102890 Engulfment and cell motility 3 16 67199111-67204029 Predicted intracellular proteins Evidence at protein level HPA021484 Approved Approved Plasma membrane
Cell Junctions Renal cancer:2.77e-5 (favourable) Expressed in all Mixed skin: 39.4 EMC4 FLJ90746, MGC24415, PIG17, TMEM85 ENSG00000128463 ER membrane protein complex subunit 4 15 34224999-34230156 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA026868, HPA053440 Approved Approved Cell Junctions
Focal adhesion sites Expressed in all Expressed in all epididymis: 120.7 F11R CD321, JAM-1, JAM-A, JAM1, JAMA, JCAM, PAM-1 ENSG00000158769 F11 receptor 1 160995211-161021348 CD markers, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB004671, HPA043616, HPA061700 Supported Approved Cell Junctions
Microtubules Expressed in all Expressed in all lung: 95.1 FAM126B HYCC2, MGC39518 ENSG00000155744 Family with sequence similarity 126, member B 2 200973718-201071671 Predicted intracellular proteins Evidence at protein level HPA036166, HPA036167, HPA067307 Uncertain Supported Nucleus
Cell Junctions Expressed in all Mixed cerebral cortex: 15.0 FAM73B C9orf54, FLJ00199, FLJ14596 ENSG00000148343 Family with sequence similarity 73, member B 9 129036621-129072082 Predicted membrane proteins Evidence at protein level HPA041363 Approved Approved Cell Junctions
Cytosol Pancreatic cancer:3.04e-6 (favourable) Expressed in all Mixed small intestine: 15.8 FBLN7 FLJ37440, TM14 ENSG00000144152 Fibulin 7 2 112138385-112188216 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA034992 Uncertain Approved Plasma membrane
Cell Junctions Mixed Mixed parathyroid gland: 18.3 FOXA2 HNF3B ENSG00000125798 Forkhead box A2 20 22581005-22585455 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB001388, HPA066846 Approved Supported Nucleoplasm
Cell Junctions Endometrial cancer:7.57e-6 (favourable), Pancreatic cancer:2.34e-4 (favourable), Ovarian cancer:6.28e-4 (favourable) Mixed Tissue enhanced cervix, uterine: 21.3;lung: 20.6;stomach: 31.3 liver: 11.5 FZD2 ENSG00000180340 Frizzled class receptor 2 17 44557459-44559570 Cancer-related genes, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA057667 Uncertain Approved Nuclear bodies
Cell Junctions Expressed in all Mixed placenta: 4.9 GAS2L1 GAR22 ENSG00000185340 Growth arrest-specific 2 like 1 22 29306582-29312785 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA019858 Approved Approved Plasma membrane
Cell Junctions Renal cancer:8.44e-4 (favourable) Expressed in all Expressed in all testis: 32.2 GID8 bA305P22.1, C20orf11, FLJ20602, TWA1 ENSG00000101193 GID complex subunit 8 20 62938119-62948475 Predicted intracellular proteins Evidence at protein level HPA049929, HPA055047 Approved Supported Nucleoplasm
Cell Junctions Renal cancer:3.22e-4 (favourable), Endometrial cancer:4.78e-4 (unfavourable) Expressed in all Expressed in all skin: 32.5 GJB3 CX31, DFNA2, EKV ENSG00000188910 Gap junction protein, beta 3, 31kDa 1 34781189-34786369 Disease related genes, Predicted membrane proteins Evidence at protein level HPA074472 Supported Vesicles
Cell Junctions Pancreatic cancer:7.56e-5 (unfavourable), Lung cancer:4.56e-4 (unfavourable) Mixed Tissue enhanced esophagus: 33.7;skin: 77.4 tonsil: 12.1 GTF2F1 BTF4, RAP74, TF2F1, TFIIF ENSG00000125651 General transcription factor IIF, polypeptide 1, 74kDa 19 6379569-6393981 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA022793, HPA028707 Approved Validated Nucleus
Cell Junctions Endometrial cancer:8.39e-4 (favourable), Renal cancer:9.80e-4 (favourable) Expressed in all Expressed in all ovary: 93.6 HLA-DPB1 HLA-DP1B ENSG00000223865 Major histocompatibility complex, class II, DP beta 1 6 33075926-33087201 Predicted membrane proteins Evidence at protein level HPA011078, HPA058509 Approved Approved Nucleus
Cell Junctions Endometrial cancer:3.38e-4 (favourable) Expressed in all Expressed in all spleen: 174.2 HOXD4 HOX4, HOX4B ENSG00000170166 Homeobox D4 2 176151222-176153226 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA054383, HPA070349 Approved Validated Nucleus
Cell Junctions Tissue enhanced Tissue enhanced endometrium: 23.5;epididymis: 22.6 fallopian tube: 15.4 IGSF23 ENSG00000216588 Immunoglobulin superfamily, member 23 19 44613630-44636781 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA051811, HPA054591 Uncertain Approved Nucleus
Cell Junctions Liver cancer:7.20e-6 (favourable) Tissue enriched Group enriched 7 duodenum: 15.6;liver: 13.1;small intestine: 17.8 testis: 2.3 ILK ENSG00000166333 Integrin-linked kinase 11 6603708-6610874 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004041, HPA048437 Supported Validated Cell Junctions
Focal adhesion sites Renal cancer:2.44e-4 (favourable) Expressed in all Expressed in all seminal vesicle: 554.5 IQGAP1 HUMORFA01, KIAA0051, p195, SAR1 ENSG00000140575 IQ motif containing GTPase activating protein 1 15 90388218-90502243 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB013302, HPA014055 Supported Supported Plasma membrane
Cell Junctions Pancreatic cancer:5.67e-5 (unfavourable) Expressed in all Expressed in all endometrium: 119.6 IREB2 IRP2 ENSG00000136381 Iron-responsive element binding protein 2 15 78437431-78501456 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB032885, HPA040371, HPA068982 Uncertain Approved Cell Junctions
Cytosol Expressed in all Expressed in all thyroid gland: 47.9 KCNK13 K2p13.1, THIK-1, THIK1 ENSG00000152315 Potassium channel, two pore domain subfamily K, member 13 14 90061765-90185857 Predicted membrane proteins, Voltage-gated ion channels Evidence at transcript level HPA003514 Approved Approved Nuclear speckles
Cell Junctions Mixed Tissue enhanced parathyroid gland: 14.3;testis: 14.4 kidney: 3.3 KIAA1462 JCAD ENSG00000165757 KIAA1462 10 30012800-30115494 Predicted intracellular proteins Evidence at protein level HPA017956 Approved Supported Vesicles
Cell Junctions Stomach cancer:2.01e-4 (unfavourable), Renal cancer:2.54e-4 (unfavourable) Expressed in all Mixed placenta: 48.3 LMTK3 KIAA1883, LMR3, PPP1R101, TYKLM3 ENSG00000142235 Lemur tyrosine kinase 3 19 48485271-48513189 Enzymes, Predicted membrane proteins Evidence at protein level HPA040203 Approved Nucleoplasm
Cell Junctions Renal cancer:3.18e-8 (favourable) Mixed Group enriched 5 cerebral cortex: 20.4;parathyroid gland: 4.8 duodenum: 2.3 LNX1 LNX, MPDZ, PDZRN2 ENSG00000072201 Ligand of numb-protein X 1, E3 ubiquitin protein ligase 4 53459301-53701405 Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA002235, HPA071091 Approved Supported Cell Junctions
Cytosol Renal cancer:3.08e-7 (favourable) Expressed in all Mixed placenta: 41.1 MAGI1 AIP3, BAIAP1, BAP1, MAGI-1, TNRC19, WWP3 ENSG00000151276 Membrane associated guanylate kinase, WW and PDZ domain containing 1 3 65353525-66038834 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA031851, HPA031852, HPA031853 Approved Validated Nucleoplasm
Cell Junctions Renal cancer:4.55e-8 (favourable) Expressed in all Mixed thyroid gland: 18.8 MAP2K4 JNKK1, MEK4, MKK4, PRKMK4, SERK1 ENSG00000065559 Mitogen-activated protein kinase kinase 4 17 12020824-12143830 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB007751, HPA060074 Supported Approved Nucleoplasm
Cell Junctions Expressed in all Expressed in all cerebral cortex: 64.2 MAP3K12 DLK, MEKK12, MUK, ZPK, ZPKP1 ENSG00000139625 Mitogen-activated protein kinase kinase kinase 12 12 53479669-53500063 Enzymes, Predicted intracellular proteins Evidence at protein level HPA039936, HPA071996 Approved Approved Nucleus
Cell Junctions Renal cancer:5.43e-10 (unfavourable), Pancreatic cancer:1.51e-4 (favourable) Mixed Mixed gallbladder: 24.0 MEPCE BCDIN3, FLJ20257, MePCE ENSG00000146834 Methylphosphate capping enzyme 7 100428790-100434126 Predicted intracellular proteins Evidence at protein level CAB026384, HPA051587 Supported Approved Nucleoplasm
Cell Junctions Renal cancer:1.01e-10 (favourable), Endometrial cancer:6.01e-6 (unfavourable) Expressed in all Expressed in all testis: 87.7 MOAP1 MAP-1, PNMA4 ENSG00000165943 Modulator of apoptosis 1 14 93182196-93184928 Predicted intracellular proteins Evidence at protein level HPA000939 Uncertain Approved Nucleus
Cell Junctions Lung cancer:7.37e-9 (favourable), Renal cancer:3.15e-6 (favourable) Expressed in all Expressed in all cerebral cortex: 86.4 MRPS18B C6orf14, HSPC183, MRPS18-2, PTD017 ENSG00000204568 Mitochondrial ribosomal protein S18B 6 30617709-30626395 Predicted intracellular proteins, Ribosomal proteins Evidence at protein level HPA043485, HPA050334 Supported Supported Cell Junctions
Mitochondria Renal cancer:3.99e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 13.2 MTFR1L FAM54B ENSG00000117640 Mitochondrial fission regulator 1-like 1 25818640-25832942 Predicted intracellular proteins Evidence at protein level HPA027124, HPA027130 Approved Approved Cell Junctions
Mitochondria Renal cancer:5.89e-12 (favourable), Endometrial cancer:6.81e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 155.3 MVD MPD ENSG00000167508 Mevalonate (diphospho) decarboxylase 16 88651935-88663161 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041404, HPA048250 Uncertain Approved Cell Junctions
Cytosol Endometrial cancer:2.17e-4 (favourable) Expressed in all Expressed in all duodenum: 34.8 NAMPT PBEF, PBEF1 ENSG00000105835 Nicotinamide phosphoribosyltransferase 7 106248285-106286326 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB034349, HPA047776, HPA057722 Approved Approved Nuclear speckles
Cell Junctions Renal cancer:2.49e-6 (unfavourable), Pancreatic cancer:1.51e-4 (unfavourable), Cervical cancer:4.78e-4 (unfavourable), Head and neck cancer:8.81e-4 (unfavourable) Expressed in all Expressed in all appendix: 792.4 NEU1 NEU ENSG00000204386 Sialidase 1 (lysosomal sialidase) 6 31857659-31862906 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA015634, HPA021506 Approved Supported Vesicles
Cell Junctions Expressed in all Mixed thyroid gland: 14.3 NUMB C14orf41 ENSG00000133961 Numb homolog (Drosophila) 14 73275107-73463642 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB011478 Approved Approved Cell Junctions
Cytosol Renal cancer:2.32e-6 (favourable) Expressed in all Expressed in all lung: 78.1 OCLN PPP1R115 ENSG00000197822 Occludin 5 69492292-69558104 Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA005933, CAB013075, CAB068212, CAB068213, CAB068214 Supported Supported Plasma membrane
Cell Junctions Renal cancer:6.59e-11 (favourable) Mixed Tissue enhanced thyroid gland: 78.3 lung: 39.9 PAK4 ENSG00000130669 P21 protein (Cdc42/Rac)-activated kinase 4 19 39125770-39182816 Enzymes, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB025747, CAB044670, HPA070175, HPA072220 Uncertain Supported Plasma membrane
Cell Junctions Renal cancer:5.29e-5 (favourable), Prostate cancer:9.85e-4 (unfavourable) Expressed in all Expressed in all prostate: 42.2 PCDH7 BH-Pcdh, PPP1R120 ENSG00000169851 Protocadherin 7 4 30720415-31146805 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA011866, HPA046521 Uncertain Validated Plasma membrane
Cell Junctions Lung cancer:6.46e-5 (unfavourable), Stomach cancer:6.42e-4 (unfavourable) Mixed Mixed cerebral cortex: 46.1 PCDHA11 CNR7, CNRN7, CNRS7, CRNR7, PCDH-ALPHA11 ENSG00000249158 Protocadherin alpha 11 5 140868183-141012344 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA077160 Approved Vesicles
Cell Junctions Not detected Tissue enhanced cerebral cortex: 7.6;parathyroid gland: 4.7 testis: 2.3 PCDHGA7 PCDH-GAMMA-A7 ENSG00000253537 Protocadherin gamma subfamily A, 7 5 141382739-141512979 Predicted membrane proteins Evidence at transcript level HPA008755, HPA077995 Uncertain Uncertain Plasma membrane
Cell Junctions Mixed Tissue enhanced cerebral cortex: 7.4 thyroid gland: 3.2 PKP2 ENSG00000057294 Plakophilin 2 12 32790745-32896840 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA014314, HPA056908 Approved Validated Nucleoplasm
Cell Junctions Lung cancer:6.79e-4 (unfavourable), Colorectal cancer:8.55e-4 (favourable) Mixed Tissue enhanced fallopian tube: 113.1;heart muscle: 114.5 parathyroid gland: 50.2 PKP4 p0071 ENSG00000144283 Plakophilin 4 2 158456964-158682879 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB037334, HPA066647, HPA070648 Approved Validated Plasma membrane
Cell Junctions Renal cancer:3.29e-7 (favourable), Endometrial cancer:5.80e-4 (favourable) Expressed in all Expressed in all kidney: 65.1 PLEKHA7 DKFZp686M22243 ENSG00000166689 Pleckstrin homology domain containing, family A member 7 11 16778295-17014443 Predicted intracellular proteins Evidence at protein level HPA038610 Approved Supported Cell Junctions
Cytosol Renal cancer:1.89e-15 (favourable) Mixed Mixed parathyroid gland: 38.8 PRR15 ENSG00000176532 Proline rich 15 7 29563811-29567295 Predicted intracellular proteins Evidence at protein level HPA040996, HPA048121 Supported Uncertain Vesicles
Cell Junctions Renal cancer:1.83e-6 (favourable), Endometrial cancer:6.37e-4 (favourable), Lung cancer:7.23e-4 (unfavourable) Mixed Tissue enhanced cervix, uterine: 91.8 colon,small intestine: 80.6 PVRL2 CD112, HVEB, PRR2, PVRR2 ENSG00000130202 Poliovirus receptor-related 2 (herpesvirus entry mediator B) 19 44846175-44889228 CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012759, CAB026138, HPA073459 Supported Uncertain Nucleoli fibrillar center
Cell Junctions Expressed in all Expressed in all placenta: 111.0 RAB25 CATX-8 ENSG00000132698 RAB25, member RAS oncogene family 1 156061160-156070514 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA010872, CAB033645 Approved Uncertain Cell Junctions
Cytosol Renal cancer:1.38e-6 (favourable) Mixed Tissue enhanced esophagus: 298.6 skin: 169.3 RASA4B ENSG00000170667 RAS p21 protein activator 4B 7 102482445-102517781 Predicted intracellular proteins, RAS pathway related proteins Evidence at transcript level HPA043010 Uncertain Uncertain Vesicles
Cell Junctions Not detected Tissue enhanced skeletal muscle: 39.7 cerebral cortex: 15.7 RSC1A1 RS1 ENSG00000215695 Regulatory solute carrier protein, family 1, member 1 1 15659869-15661722 Predicted intracellular proteins Evidence at protein level HPA027813, HPA028676 Approved Supported Nucleoplasm
Cell Junctions Not detected Mixed smooth muscle: 5.2 SAMD4A DKFZP434H0350, hSmaug1, KIAA1053, SAMD4, Smaug, SMG, SMGA ENSG00000020577 Sterile alpha motif domain containing 4A 14 54567097-54793315 Predicted intracellular proteins Evidence at protein level HPA043061, HPA065309 Approved Approved Cell Junctions
Cytosol Expressed in all Tissue enhanced testis: 102.3 skeletal muscle: 32.7 SAPCD1 C6orf26, NG23 ENSG00000228727 Suppressor APC domain containing 1 6 31762799-31764851 Predicted intracellular proteins Evidence at transcript level HPA071699 Approved Vesicles
Cell Junctions Mixed Tissue enhanced skin: 3.2 bone marrow: 1.0 SCN8A CerIII, MED, NaCh6, Nav1.6, PN4 ENSG00000196876 Sodium channel, voltage gated, type VIII alpha subunit 12 51590266-51812864 Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level CAB022169 Supported Vesicles
Cell Junctions Mixed Tissue enriched 6 cerebral cortex: 22.1 testis: 3.5 SLC16A1 MCT, MCT1 ENSG00000155380 Solute carrier family 16 (monocarboxylate transporter), member 1 1 112911847-112957013 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA003324, CAB017489, HPA071055 Supported Validated Plasma membrane
Cell Junctions Renal cancer:6.78e-8 (unfavourable), Endometrial cancer:8.37e-6 (unfavourable), Pancreatic cancer:2.10e-4 (unfavourable), Lung cancer:4.05e-4 (unfavourable) Expressed in all Mixed testis: 32.0 SLC16A10 MCT10, TAT1 ENSG00000112394 Solute carrier family 16 (aromatic amino acid transporter), member 10 6 111087503-111231194 Predicted membrane proteins, Transporters Evidence at protein level HPA016860 Approved Approved Vesicles
Cell Junctions Tissue enriched Tissue enhanced placenta: 38.2 skin: 22.5 SLC16A9 C10orf36, FLJ43803, MCT9 ENSG00000165449 Solute carrier family 16, member 9 10 59650761-59736002 Predicted membrane proteins, Transporters Evidence at protein level HPA049286 Approved Approved Nucleus
Cell Junctions Renal cancer:2.56e-6 (favourable) Mixed Tissue enhanced adrenal gland: 199.5;kidney: 199.2 spleen: 57.0 SLC23A3 FLJ31168, SVCT3, Yspl1 ENSG00000213901 Solute carrier family 23, member 3 2 219161465-219170095 Predicted membrane proteins, Transporters Evidence at protein level HPA019059 Approved Nucleus
Cell Junctions Tissue enriched Tissue enhanced kidney: 52.7;small intestine: 23.3 duodenum: 9.0 SLC26A9 ENSG00000174502 Solute carrier family 26 (anion exchanger), member 9 1 205913048-205943460 Predicted membrane proteins, Transporters Evidence at protein level HPA051485 Approved Approved Nucleus
Cell Junctions Head and neck cancer:8.55e-5 (favourable) Tissue enhanced Tissue enhanced salivary gland: 31.7;stomach: 30.4 lung: 11.4 SLC2A11 GLUT10, GLUT11 ENSG00000133460 Solute carrier family 2 (facilitated glucose transporter), member 11 22 23856703-23886309 Predicted membrane proteins, Transporters Evidence at transcript level HPA042960, HPA071184 Uncertain Uncertain Nucleus
Cell Junctions Renal cancer:5.77e-7 (favourable), Pancreatic cancer:3.83e-4 (favourable) Mixed Mixed parathyroid gland: 10.7 SLC2A12 GLUT12, GLUT8 ENSG00000146411 Solute carrier family 2 (facilitated glucose transporter), member 12 6 133988697-134052636 Predicted membrane proteins, Transporters Evidence at protein level HPA031593, HPA031594 Approved Validated Plasma membrane
Cell Junctions Tissue enriched Tissue enhanced prostate: 38.8 endometrium: 15.7 SLC44A2 CTL2 ENSG00000129353 Solute carrier family 44 (choline transporter), member 2 19 10602457-10644559 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA003228, HPA070799 Approved Approved Vesicles
Cell Junctions Renal cancer:1.71e-5 (favourable), Pancreatic cancer:6.01e-4 (unfavourable) Expressed in all Expressed in all placenta: 224.3 SLC6A6 TAUT ENSG00000131389 Solute carrier family 6 (neurotransmitter transporter), member 6 3 14402576-14489349 Predicted membrane proteins, Transporters Evidence at protein level HPA015028, HPA016488 Supported Approved Cell Junctions
Cytosol Glioma:1.09e-7 (unfavourable), Endometrial cancer:5.22e-5 (favourable), Liver cancer:8.78e-4 (unfavourable) Expressed in all Mixed ovary: 50.7 SLC7A2 ATRC2, CAT-2, HCAT2 ENSG00000003989 Solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 8 17497088-17570573 Predicted membrane proteins, Transporters Evidence at protein level HPA009277 Supported Plasma membrane
Cell Junctions Renal cancer:2.65e-7 (unfavourable), Stomach cancer:3.08e-4 (unfavourable) Expressed in all Tissue enhanced parathyroid gland: 373.7 liver: 92.6 SLC9B2 FLJ23984, NHA2, NHEDC2 ENSG00000164038 Solute carrier family 9, subfamily B (NHA2, cation proton antiporter 2), member 2 4 103019868-103085829 Predicted membrane proteins, Transporters Evidence at protein level HPA047008 Uncertain Approved Nucleoplasm
Cell Junctions Expressed in all Tissue enhanced cerebral cortex: 32.6 liver: 20.5 SNX32 FLJ30934, SNX6B ENSG00000172803 Sorting nexin 32 11 65833641-65856896 Predicted intracellular proteins Evidence at protein level HPA041775 Uncertain Uncertain Cell Junctions
Focal adhesion sites Mixed Tissue enhanced cerebral cortex: 7.8 testis: 1.7 SORL1 C11orf32, gp250, LR11, LRP9, SorLA, SorLA-1 ENSG00000137642 Sortilin-related receptor, L(DLR class) A repeats containing 11 121452203-121633693 Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB011500, HPA031321 Uncertain Approved Nucleoplasm
Cell Junctions Renal cancer:1.80e-7 (favourable) Expressed in all Mixed cervix, uterine: 67.4 SPERT CBY2, NURIT ENSG00000174015 Spermatid associated 13 45702311-45714559 Predicted intracellular proteins Evidence at protein level HPA039359, HPA040046 Supported Approved Plasma membrane
Cell Junctions Mixed Tissue enriched 175 testis: 49.2 fallopian tube,urinary bladder: 0.2 SPTBN2 SCA5 ENSG00000173898 Spectrin, beta, non-erythrocytic 2 11 66685248-66729226 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB009844, HPA039293, HPA043529 Supported Supported Cell Junctions
Cytosol Pancreatic cancer:3.14e-5 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 73.2;skin: 59.4;testis: 48.5 parathyroid gland: 24.2 SYT8 DKFZp434K0322 ENSG00000149043 Synaptotagmin VIII 11 1828307-1837521 Predicted membrane proteins Evidence at transcript level HPA052700 Uncertain Approved Nucleoplasm
Cell Junctions Tissue enhanced Group enriched 5 gallbladder: 26.7;skin: 80.3;urinary bladder: 25.5 seminal vesicle: 8.5 TBC1D24 DFNA65, DFNB86, KIAA1171, TLDC6 ENSG00000162065 TBC1 domain family, member 24 16 2475118-2505734 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA044712, HPA068080 Uncertain Supported Plasma membrane
Cell Junctions Breast cancer:3.22e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 23.4 TJP3 ZO-3 ENSG00000105289 Tight junction protein 3 19 3708109-3750813 Predicted intracellular proteins Evidence at protein level CAB013244, HPA046863, HPA053337 Supported Validated Nucleoplasm
Cell Junctions Renal cancer:9.36e-8 (favourable), Endometrial cancer:1.83e-6 (favourable), Head and neck cancer:9.52e-4 (favourable) Mixed Tissue enhanced duodenum: 42.7;small intestine: 42.1 colon: 31.1 TMEM141 MGC14141 ENSG00000244187 Transmembrane protein 141 9 136791355-136793257 Predicted membrane proteins Evidence at protein level HPA014615, HPA050244 Approved Supported Cell Junctions
Mitochondria Renal cancer:6.63e-4 (favourable) Expressed in all Expressed in all prostate: 214.3 TMEM164 FLJ22679, RP13-360B22.2 ENSG00000157600 Transmembrane protein 164 X 110002631-110182734 Predicted membrane proteins Evidence at protein level HPA038784 Approved Approved Vesicles
Cell Junctions Liver cancer:8.17e-6 (unfavourable), Stomach cancer:3.14e-4 (favourable) Expressed in all Expressed in all lung: 26.7 TMEM251 C14orf109, DKFZP564F1123 ENSG00000153485 Transmembrane protein 251 14 93184951-93187089 Predicted membrane proteins Evidence at transcript level HPA048559 Uncertain Approved Golgi apparatus
Cell Junctions Liver cancer:6.14e-7 (unfavourable), Renal cancer:1.10e-4 (favourable) Expressed in all Expressed in all prostate: 27.9 TMPRSS2 PRSS10 ENSG00000184012 Transmembrane protease, serine 2 21 41464551-41531116 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA034493, HPA035787 Supported Supported Nucleoplasm
Cell Junctions Renal cancer:7.86e-6 (favourable), Endometrial cancer:2.56e-4 (favourable) Tissue enriched Tissue enhanced prostate: 495.7 stomach: 142.5 TP53BP2 53BP2, ASPP2, PPP1R13A ENSG00000143514 Tumor protein p53 binding protein 2 1 223779899-223845972 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA021603, HPA050429 Supported Validated Cell Junctions
Cytosol Expressed in all Expressed in all thyroid gland: 34.4 WRAP73 WDR8 ENSG00000116213 WD repeat containing, antisense to TP73 1 3630767-3652761 Predicted intracellular proteins Evidence at protein level HPA026893 Uncertain Approved Nucleoplasm
Cell Junctions Liver cancer:1.37e-4 (unfavourable), Renal cancer:1.42e-4 (unfavourable), Pancreatic cancer:3.49e-4 (favourable) Expressed in all Expressed in all lymph node: 20.7 ZNF497 FLJ44773 ENSG00000174586 Zinc finger protein 497 19 58354357-58362848 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA047872 Uncertain Approved Nucleus
Cell Junctions Mixed Mixed fallopian tube: 10.7